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Children with solid tumors represent a unique population. Recent improvements in pedi-
atric solid tumor survival rates have been confined to low- and moderate-risk cancers,
whereas minimal to no notable improvement in survival have been observed in high-risk and
advanced-stage childhood tumors.Treatments for patients with advanced disease are rarely
curative, and responses to therapy are often followed by relapse, which highlights the large
unmet need for novel therapies. Recent advances in cancer treatment have focused on
personalized therapy, whereby patients are treated with agents that best target the molec-
ular drivers of their disease.Thus, a better understanding of the pathways that drive cancer
or drug resistance is of critical importance. One such example is the phosphatidylinositol
3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway, which is activated
in many solid cancer patients and represents a target for therapy. PI3K/Akt/mTOR path-
way activation has also been observed in tumors resistant to agents targeting upstream
receptor tyrosine kinases (RTKs). Agents that target this pathway have the potential to shut
down survival pathways, and are being explored both in the setting of pathway-activating
mutations and for their ability to restore sensitivity to upstream signaling targeted agents.
Here, we examine the role of the PI3K/Akt/mTOR pathway in pediatric solid tumors, review
the novel agents being explored to target this pathway, and explore the potential role of
the inhibition of this pathway in the clinical development of these agents in children.
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INTRODUCTION
THE PI3K SIGNALING PATHWAY
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases that phos-
phorylate the inositol ring of phosphoinositides. They generate
second messengers that control cell proliferation, survival, motil-
ity, and morphological changes. They are grouped into three
classes according to structure, substrate specificity, and tissue
distribution. Class I PI3Ks are activated by cell surface recep-
tors – Class IA by receptor tyrosine kinases (RTKs) and Class IB
by G-protein-coupled receptors. They are involved in cell growth,
proliferation, and survival. Class II PI3Ks are activated by RTKs,
cytokine receptors, and integrins, and may have a role in regula-
tion of membrane trafficking and receptor internalization. Class
III PI3Ks utilize only phosphatidylinositol as substrate. They reg-
ulate downstream targets in response to amino-acid availability
and cellular stress, and are involved in cell survival and growth.
Class IA PI3Ks are the most commonly implicated in cell divi-
sion and tumorigenesis. They are composed of heterodimers of a
p110α catalytic subunit, and a p85 α regulatory subunit that main-
tains the former in a quiescent state. The SH2 domain (src onco-
gene homology-2 domain) of the p85α subunit binds to growth
factor receptor and non-receptor protein tyrosine kinases. These
include epidermal growth factor receptor (EGFR), platelet-derived
growth factor receptor (PDGFR), fibroblast growth factor receptor
(FGFR), vascular endothelial growth factor receptor (VEGFR),
insulin-like growth factor 1 receptor (IGF-1R), interleukin recep-
tors, interferon receptors, and integrin receptors. This binding
releases the p110α subunit inhibition and recruits the complex
from the cytoplasm to receptor sites on the inner cell membrane
(Jiang and Liu, 2008).
Activation of the p110α subunit leads to phosphorylation of
its substrate phosphatidylinositol 4,5-bisphosphate (PIP2) at the
3-position of the inositol ring, forming the second messenger
phosphatidylinositol 3,4,5-triphosphate (PIP3). PIP3 – which is
degraded by PTEN, as well as SHIP1 and SHIP2 – recruits Pleck-
strin Homology (PH) domain-containing proteins to cellular
membranes. Among them is Akt, also known as protein kinase
B (PKB). At the membrane, PKB/Akt is phosphorylated at Thr308
by PDK1 and at Ser473 by the mammalian target of Rapamycin
(mTOR)C2 complex. Upon activation,Akt moves to the cytoplasm
and nucleus and phosphorylates multiple downstream targets
involved in the regulation of various cellular functions (Figure 1).
Key downstream cellular processes induced by Akt include
increased cell metabolism and glycogen synthesis via inhibition
of the FOXO (forkhead) family and glycogen synthase kinase
3 (GSK3); blockade of apoptosis via inhibition of p53, NF-κB,
and BAD (Bcl2-antagonist of cell death); and increased pro-
tein synthesis and cell proliferation via activation of the mTOR
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FIGURE 1 |The PI3K signaling pathway and the downstream targets of Akt.
complex 1 (mTOR-raptor kinase complex, or mTORC1) (Carnero,
2010).
PI3K PATHWAY MUTATIONS IN HUMAN CANCER
Constitutive activation due to deregulation of the PI3K pathway
has been implicated in multiple human cancers (Hennessy et al.,
2005). The commonest are activating point mutations of PI3K,
inactivation of the tumor suppressor PTEN, and amplification of
the Akt gene.
Gain of function mutations of PI3K have been observed in
many human adult cancers, including ovarian, breast, gastric, and
hepatocellular carcinoma. These include increased copy numbers
and activating somatic mutations of PI3KCA, the gene encoding
the p110α catalytic subunit of PI3K (Samuels and Ericson, 2006;
Ligresti et al., 2009). This mutation is more commonly encoun-
tered in adult cancers and associated with a more aggressive clinical
course, but is less commonly seen in pediatric malignancies. Other
mechanisms may be responsible for activating the PI3K pathway
in childhood cancers. Other known genetic aberrations involving
PI3K include deletion and somatic mutations of PIK3R1, the gene
encoding the p85 regulatory subunit, have been noted in colon
and ovarian carcinomas, and glioblastoma.
Phosphatase and tensin homolog deleted on chromosome 10
(PTEN) is the antagonist of PI3K. Inactivating mutations of PTEN
are encountered in lung, kidney, endometrial and breast carcino-
mas, melanomas, and glioblastomas. Decreased PTEN expression
is negatively correlated with survival outcomes of ovarian, prostate
and cervical cancers. Germline mutations of PTEN are associated
with the PTEN hamartoma-tumor syndromes (PHTS), a fam-
ily of hamartomatous polyposis syndromes including Cowden
syndrome, Bannayan–Riley–Ruvalcaba syndrome, Proteus syn-
drome, and Proteus-like syndrome (Chow and Baker, 2006).
Akt gene amplification has been observed in cases of gastric
carcinoma, glioblastoma, and gliosarcoma. Amplification of its
isoforms have also been reported in various human cancers: Akt2
in pancreatic, ovarian, breast, and head and neck squamous cell
carcinomas, and Akt3 in breast and prostate cancers. An acti-
vating somatic mutation of Akt1 (Akt-E17K) has been reported
in human breast, colorectal, and ovarian cancers. This mutation
induces plasma membrane localization, downstream signaling,
and transforms cells, and induces leukemia in mice.
As a collective group, brain tumors are the commonest solid
tumors in children. The commonest extracranial solid tumors
are neuroblastoma (NB), osteosarcoma, Ewing sarcoma family
of tumors (ESFT), rhabdomyosarcoma (RMS), germ cell tumors,
and Wilms tumor. The overall survival rate of the former four
tumors in the advanced stage remains less than 30% despite inten-
sive efforts over the past three decades using multiple therapeutic
modalities including chemotherapy, surgery, radiation, autologous
bone marrow transplant, and biological agents. The PI3K signal-
ing pathway has been implicated in the tumorigenesis of NB, ESFT,
RMS, and osteosarcoma, and this review will focus on these tumor
types, and discuss chemotherapeutic agents in current pediatric
preclinical and clinical trials.
PI3K SIGNALING IN PEDIATRIC SOLID TUMORS
PI3K SIGNALING IN NEUROBLASTOMA
Despite current multi-modal treatments comprising chemother-
apy, surgical gross total resection, radiotherapy, stem cell trans-
plantation, and immunotherapy, high-risk cases of NB still have
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a very poor prognosis despite aggressive therapy, often recurring
with chemoresistant metastases. This tumor alone accounts for
more than 10% of all pediatric cancer deaths. Clearly, new treat-
ment strategies are needed particularly for high-risk patients. This
tumor most commonly arises in the retroperitoneum from the
adrenal glands and paravertebral sympathetic plexuses. It is highly
vascular in nature, and wraps around major abdominal vessels,
developing extensive tumor neovasculature. This reflects activa-
tion of angiogenic and tumorigenic pathways, many of which are
activated through RTKs which trigger PI3K signaling.
Activation of the PI3K signaling pathway has been demon-
strated as a common event in NB cells. In an analysis of 39
samples of high-risk tumors, high levels of PI3Kp85 and PI3Kp110
expression were seen in the cytoplasm in 54% of cases (Iz˙ycka-
Swieszewska et al., 2010). However, activating gene mutations of
PI3KCA and the loss of function mutations of tumor suppres-
sor PTEN are very rarely present in NB, even though they are
commonly seen in other human cancers. Sequencing data from
42 primary human NB tumors and 27 cell lines found activating
mutations in the PI3KCA gene in only 2.9% of samples, and this
mutation rate did not differ significantly between those with and
without MYCN amplification (Dam et al., 2006). Using RT-PCR,
Muñoz et al. (2004) found homozygous deletions of PTEN in only
2 of 41 (5%) primary tumors, and in none of 12 cell lines.
Phosphatidylinositol 3-kinase pathway activation in NB may
take place via different mechanisms. Decreased PTEN expression
may play a role in inducing PI3K signaling in NB tumorigenesis via
decreased negative regulation on the p110 subunit. This hypothesis
is supported by observations of decreased PTEN protein expres-
sion seen on immunohistochemical analysis. A decrease in the
ratio of PTEN to phospho-Akt protein expression was observed in
undifferentiated tumors (Qiao et al., 2005). Also, decreased inten-
sity of nuclear expression of PTEN has been observed in up to a
third of cases (Iz˙ycka-Swieszewska et al., 2010).
Correspondingly, activation of downstream targets of the PI3K
pathway have been demonstrated in NB tumor cells. Akt activation
has been shown to correlate with a poorer prognostic outcome
in NB, and is associated with other markers of aggressive dis-
ease, including NMYC amplification, advanced disease stage and
unfavorable histology (Opel et al., 2007). On immunohistochem-
istry, intense phospho-Akt staining is observed in undifferentiated
and poorly differentiated neuroblasts. The degree of neuroblast
differentiation has been observed to correlate inversely with the
expression of phospho-Akt – which is seen almost exclusively in
the cytoplasm. Akt phosphorylation activates downstream mTOR
kinase. In the same study, a statistically significant association was
demonstrated between phospho-Akt and phospho-mTOR expres-
sion (Qiao et al., 2005). In a series of 30 primary NB tumor
samples, phospho-Akt and mTOR was detected in all samples,
but was not seen in the Schwannian stroma and non-malignant
adrenal medulla (Johnsen et al., 2008). Our laboratory is presently
investigating the significance of differential phosphorylation lev-
els of Akt and mTOR in NB cell lines and xenografts, as well as
differential phosphorylation at the key activation sites Thr308 and
Ser473.
mTOR is a major controller of cell growth and a negative regu-
lator of autophagy, and its activity in NB cells has been shown
to affect cell differentiation by regulating the balance between
macromolecule synthesis and degradation. In the first morpho-
proteomic study performed on three samples of high-risk pri-
mary human NB tumors, Brown et al. (2007) found activation of
the mTOR/p70S6K, NFkB, and ERK 1/2 pathways. Conversely,
decreased activation of the mTOR pathway is associated with
increased neuroblastic differentiation. Using mouse NB N2a cells
in culture, Zeng et al. showed that downregulation of Akt-mTOR
signaling accompanied differentiation of murine NB cells induced
by treatment with retinoic acid. This occurred in the same time-
dependent pattern as the induction of autophagy as indicated by
the relative expression of the autophagy protein LC3 (Zeng and
Zhou, 2008).
PI3K SIGNALING IN EWING SARCOMA FAMILY OF TUMORS
The ESFTs is thought to arise from primordial bone marrow-
derived mesenchymal stem cells, and encompass primitive neu-
roectodermal tumors, Askin tumor (Ewing sarcoma of chest
wall), and extraosseous Ewing sarcomas. They are character-
ized by distinctive karyotypic abnormalities involving the EWSR1
locus on chromosome 22 band q12, which forms fusion prod-
ucts with different members of the Ets family of transcription
factors (de Alava and Gerald, 2000). The commonest transloca-
tion t(11;22)(q24;q12), involving Fli-1, is reported in more than
85% of ESFTs. Other common translocations include t(21;22),
t(7;22), and t(17;22), involving the ERG, ETV1, and E1AF genes,
respectively.
These fusion proteins act as abnormal transcription factors, and
also influence post-transcriptional RNA processing. The EWS/Fli-
1 fusion product has been shown to transform murine fibroblasts
in vitro through a mechanism involving IGF-1. In these fibrob-
lasts transformed with the ESW/Fli-1 fusion protein, IGF-1 acts
via IRS-1 (Insulin receptor substrate 1), which moves from a low
to high phosphorylation state and transmits signals to activate
PI3K (Toretsky et al., 1997). Separately, IGF-1 can also activate
Ras, which then activates PI3K. IGF-1 is a major survival factor
that induces neoplastic transformation and diminished apopto-
sis, and is implicated in the carcinogenesis of prostate, breast, and
other cancers. All ESFTs express the IGF-1 receptor, and IGF-1
is stored in bone matrix, which is found at the site of origin of
osseous ESFTs. As such, it is suggested that ESFT tumorigene-
sis may be induced by paracrine and autocrine stimulation by
IGF-1 (Benini et al., 2004), which then activates Ras and PI3K
downstream.
The PI3K/Akt pathway mediates survival signals in ESFT via
mechanisms involving IGF-1. Downstream activation of PI3K by
IGF-1 has been shown to partly mediate inhibition of apoptosis
(Kulik et al., 1997; Párrizas et al., 1997), and correspondingly inhi-
bition of PI3K dramatically reduces cell proliferation in Ewing sar-
coma cell lines. PI3K inhibition sensitizes these cells to apoptosis
by FGF-2 (fibroblast growth factor 2) – a growth and differenti-
ation factor that induces growth arrest in ESFT cells (Hotfilder
et al., 2005). Constitutive activation of Akt in a transfected ESFT
cell line rendered the cells more resistant to apoptosis by Doxoru-
bicin, implicating the IGF-IR/PI3K/Akt pathway in the survival
signaling mechanisms in ESFT cells (Kulik et al., 1997; Toretsky
et al., 1999).
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The EWS/Fli-1 fusion product also plays a role in regula-
tion of telomerase activity and phospholipase D expression. The
latter occurs by activation of cell proliferation via the MEK
(mitogen-activated protein kinase)/ERK (extracellular signal-
regulated kinase) pathway and the PI3K/Akt pathway (Banno et al.,
2001). Constitutive activation of the PI3K and MEK/MAPK path-
way has been observed in ESFT cell lines maintained in standard
medium (Benini et al., 2004).
Phosphatidylinositol 3-kinase activation has been found to
be essential for cellular polarization and elongation, which are
the first steps in cell motility, the corresponding initial step
in the process of cell invasion and metastasis. In ESFT cells,
PI3K/Rac1 activation by bFGF (basic fibroblast growth factor)
induced these morphological alterations and also increased cell
motility (Kamura et al., 2010). Akt/mTOR signaling is not impli-
cated in this pathway, but is activated instead by IGF-1 (type I
insulin-like growth factor) to stimulate F-actin reorganization and
induce cell motility in both ESFT and RMS cells (Liu et al., 2008).
Activation of the PI3K pathway is implicated in the devel-
opment of chemotherapy resistance and is frequently observed
when conventional anticancer drugs are used (Yu et al., 2008).
PI3K inhibition may serve to decrease chemotherapy resistance,
in addition to its direct anticancer effects. PI3K/mTOR inhibitors
Wortmannin and LY294002 sensitized ESFT cells in culture to
increased apoptosis by various common chemotherapeutic agents.
Doxorubicin-induced apoptosis was enhanced when PI3K was
inhibited in TC-71 and TC-32 ESFT cells, as evidenced by increased
DNA fragmentation, increased caspase-3 activity, and on TUNEL
assay (Toretsky et al., 1999; Benini et al., 2004). Treatment of TC-
135 Ewing sarcoma cells with Actinomycin D induced significant
activation of the MEK/ERK and PI3K/Akt pathways. Inhibition of
pAkt with LY294002 enhanced Actinomycin D-induced caspase-
dependent cell apoptosis as determined by PARP cleavage assays.
This was not seen with p-ERK inhibition. These experiments sug-
gested that the PI3K/Akt pathway was chiefly implicated in the
mechanisms of chemotherapeutic resistance to Actinomycin D in
ESFT cells (Yamamoto et al., 2009).
PI3K SIGNALING IN RHABDOMYOSARCOMA
Rhabdomyosarcoma has several distinct histological subtypes.
Embryonal tumors are the most frequent, and account for 60–70%
of all childhood RMS. They arise most frequently in the head and
neck, and the region of the genitourinary tract. Alveolar tumors are
less common but behave more aggressively, and are more common
in the extremity, trunk, and perineal regions. Anaplastic tumors
are rarely seen in children. Distinctive molecular abnormalities
characterize the two commonest types of RMS. Up to 80% of
alveolar tumors possess the t(2;13)(q35;q14) or t(1;13)(p36;q14)
chromosomal translocations, involving the FOXO1 (FKHR) gene
on chromosome 13 and the PAX 3 or PAX 7 genes, respectively
(Shapiro et al., 1993). These fusion proteins function as transcrip-
tion factors that play a role in cell cycle dysregulation, and play a
major role in the tumorigenesis of RMS.
Phosphatidylinositol 3-kinase/Akt signaling has been known
to play a direct role in regulating myogenesis and myoblast dif-
ferentiation (Kaliman et al., 1996; Jiang et al., 1999; Li et al.,
2000). In normal physiological regulation, PI3K/Akt activation
enhances cell proliferation and migration via antagonism of the
winged-helix family of forkhead transcription factors. PI3K activa-
tion induces phosphorylation, nuclear export, and transcriptional
inactivation of FOXO1, FOXO3, FOXO4, and FOXO6. Akt directly
phosphorylates FOXO1 at Thr24 and Ser253, negatively regulat-
ing its transcription by promoting export from the nucleus. This
decreases expression of downstream target genes, which include
the pro-apoptotic Fas ligand, TRAIL, and Bim (Biggs et al., 1999;
Brunet et al., 1999). FOXO expression represses the transcription
of D-type cyclins, which regulate cell cycle G1 progression and
function as key sensors for mitogenic growth factors (Zhang et al.,
2004). Thus, the net effect of physiological PI3K/Akt activation is
enhancement of cell proliferation and migration.
In RMS, cellular proliferation occurs via distinct – though not
necessarily independent – mechanisms involving its characteris-
tic fusion products. In cells possessing the PAX7-FOXO1 fusion
transcript, phospho-Akt is upregulated with increased nuclear
localization. This upregulates NF-kappaB, which in turn sup-
presses MyoD1-mediated terminal myogenic differentiation via
cyclin-dependent kinase 4 (cdk4). In a panel of 21 human alveolar
RMS samples, 85% of the tumors displayed nuclear or cytoplasmic
expression of cdk4. It is suggested that through this mechanism,
inappropriately sustained expression of PAX7-FOXO1 fusion tran-
scripts maintains skeletal muscle precursors in an undifferenti-
ated state (Charytonowicz et al., 2012). PAX3-FOXO1 activates
PI3K/Akt signaling by downregulating PTEN. In RMS cell lines,
PAX3-FOXO1 inhibition induced PTEN upregulation. Conversely
in C2C12 myoblasts, PAX3 induction downregulated PTEN (Li
et al., 2007). In addition, physiological regulators of muscle differ-
entiation are deranged in RMS. Expression of FOXO1 is signifi-
cantly higher in RMS, even when compared with other tumors like
ESFT. MyoD, which is required for proper skeletal muscle differen-
tiation, is widely expressed in RMS cells, but functionally deficient
(Tapscott et al., 1993).
Insulin-like growth factor mediates its effects on muscle differ-
entiation via the PI3K/Akt pathway by upregulating endogenous
myogenin expression. RMS is characterized by high levels of IGF-
2, which is produced in an autocrine manner (Minniti et al., 1995).
This IGF-2 overexpression drives Akt phosphorylation. IGF-2
induction of Akt is regulated by differential phosphorylation at
Ser473, rather than at Thr308 where high levels of Akt phospho-
rylation are seen in all RMS cell lines. This IGF-2-overexpression-
mediated Akt phosphorylation at Ser473 is modulated by PTEN
protein expression levels, but the exact mechanism by which PTEN
regulates Ser473 phosphorylation of Akt is unclear. In an autocrine
loop, the PAX3-FOXO1 fusion transcript transactivates the IGF-
1R promoter, further potentiating the effects of IGF on PI3K/Akt
activation. In sarcoma-derived cell lines, the PAX3-FOXO1 fusion
protein induces a more significant rise in IGF-1 levels as compared
with PAX3 alone (Ayalon et al., 2001).
Phosphorylation levels of many receptor and non-RTKs and
serine/threonine kinases in the mTOR and PKC pathways are ele-
vated in RMS as compared with normal muscle tissue. These are
strongly implicated in the development and tumor progression of
RMS. In an analysis using 64-core primary tumor tissue microar-
rays from the Children’s Oncology Group (COG), mTOR phos-
phorylation levels were elevated in 60% of alveolar and 68% of
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embryonal cases; PKC isozymes were upregulated in up to 69% of
alveolar and 72% of embryonal cases. However, in the study, these
were not significantly correlated with clinicopathologic features
(Cen et al., 2007).
PI3K SIGNALING IN OSTEOSARCOMA
Osteosarcomas have numerous chromosomal aberrations and
complex karyotypes, with chromosomal abnormalities involving
members of the PI3K/Akt pathway (Lau et al., 2004; Man et al.,
2004). In a series of 59 pediatric patients, PTEN deletions were
observed in 12 cases (Freeman et al., 2008). In a series of 98 pri-
mary adult osteosarcomas, 40 were found to have at least 1 gene
mutation, and among these, 3 novel mutations involving PI3KCA
were observed. Yet, samples without PI3KCA mutations have been
found to have high levels of pAkt and p4EBP1, suggesting that
alternate mechanisms exist for the hyperactivation of PI3K in
osteosarcoma (Choy et al., 2012). While the tumorigenesis of this
tumor is poorly understood, cancer stem-like cells from human
and canine osteosarcoma have been isolated (Gibbs et al., 2005),
and used to study the molecular pathways involved in progression
of this tumor. The PI3K/Akt pathway has been shown to play an
important role in cell cycle regulation and apoptosis of osteosar-
coma cancer stem-like cells, with dose-dependent decrease in pAkt
expression seen following PI3K inhibition with LY204002. This
yields G0/G1 cell cycle arrest and increased apoptosis indicated by
activation of caspase-9, caspase-3, and PARP, which are involved
in the mitochondrial apoptosis pathway (Gong et al., 2012).
Phosphatidylinositol 3-kinase/Akt regulation in osteosarcoma
cells has been modulated by administration of bisphosphonates
in vitro, with resulting impacts on cell survival, and invasion.
In murine osteosarcoma cell lines, bisphosphonates inhibited
Ras/PI3K/Akt and Ras/MEK/ERK expression, which produced
decreased cell migration, invasion, and adhesion to the extracel-
lular matrix, as well as decreased mRNA expression and activity
of matrix metalloproteinases (Tsubaki et al., 2012). These zinc-
dependent endopeptidases are major components of the basement
membranes and are thought to correlate with tumor invasiveness
and metastatic potential. In addition, other agents have shown
the ability to regulate downstream targets of the PI3K pathway
through alternative mechanisms, independent of PI3K activity.
Alendronate, an amino-bisphosphonate commonly used in clin-
ical practice, inhibits Akt phosphorylation at Ser473 and Thr308
in osteosarcoma cell lines. This causes apoptosis by inhibiting
the PI3K/Akt/NFκB cell survival pathway at the initial step of
PI3K activation (Inoue et al., 2005). Zoledronic acid has been
shown to augment the effect of mTOR inhibition by Everolimus
in mice models. Everolimus inhibition alone induced marked
decrease in the rate of cell cycle phases and mitosis, but further
significant additive effects were seen with addition of Zoledronic
acid, resulting in downregulation of mTOR downstream signal-
ing involving 4EBP1 and decreased Ras isoprenylation and GTP
binding. This yielded decreased tumor development and increased
bone mass (Moriceau et al., 2010). These alternative activation
pathways may be relevant to mechanisms of tumor escape follow-
ing treatment with PI3K inhibitors, and warrant equal attention
in the overall development of targeted therapy involving this
pathway.
THERAPEUTIC TARGETING OF PI3K PATHWAY FOR
PEDIATRIC SOLID TUMOR TREATMENT
BACKGROUND
As with many clinical advances in medicine, rapamycin, derived
from Streptomyces hygroscopicus, was initially developed as a fungi-
cidal (Sehgal et al., 1975) and immunosuppressive agent used in
the setting of organ transplantation (Calne et al., 1989). Though
the anti-proliferative activity of rapamycin as an mTOR inhibitor
in preclinical models was also observed, the poor aqueous solu-
bility and chemical stability of this agent made it a poor choice
for further development in cancer therapy. However, rapamycin
derivatives (“rapalogs”) with improved pharmaceutical proper-
ties and comparable efficacy sparked further interest in the use
of this drug. Further insights regarding the molecular mechan-
ics of PI3K signaling that promote cancer cell growth and sur-
vival expanded the potential targets in this pathway, resulting in
a myriad of agents targeting PI3K, Akt, mTOR, and even dual
PI3K/mTOR inhibition. A recent review highlighted many of these
PI3K-Akt pathway inhibitors in clinical development for treating
adult cancers (Engelman, 2009). Of note, the Engelman review also
concisely addressed the challenges of identifying “sensitive” popu-
lations with particular pathway abnormalities that are most likely
to benefit from the targeted therapy and then providing the right
combination or complementation with targeted therapy to over-
come the potential for resistance due to signaling feedback loops
within this pathway. A full discussion of the success and/or failure
of these trials is beyond the scope of this review. While the clinical
route to targeting PI3K signaling in pediatric solid malignancies
shares many of the same challenges, we cannot directly extrapolate
from adult studies. Pediatric trials focusing on this pathway face
additional challenges of accrual and differences in the molecular
signature of pediatric tumors, requiring thoughtful and efficient
utilization of existing preclinical evidence to prioritize the most
active therapies (Table 1).
PI3K/Akt INHIBITION IN PEDIATRIC SOLID MALIGNANCIES
Perifosine targets the lipid-binding PH domain of Akt and inhibits
the translocation of Akt to the cell membrane, an essential step
for Akt activation (Richardson et al., 2012). It decreases Akt
phosphorylation and increases caspase-dependent apoptosis in
NB cell lines, inhibits growth of NB xenografts, and overcomes
RTK/ligand-mediated chemoresistance (Li et al., 2010, 2011).
It is currently being studied in two Phase I clinical trials in
children with recurrent or refractory solid tumors. In the sin-
gle agent trial (ClinicalTrials.gov identifier NCT00776867), the
maximum-tolerated dose (MTD) has not yet been reached. The
study opened in 2008 and is expected to accrue 36 participants
through 2013. In the second study (NCT01049841), patients are
treated with a combination of perifosine and the mTOR-inhibitor
temsirolimus based on preclinical data showing synergy of the
two agents. It is hypothesized that direct Akt inhibition may over-
come Akt activation secondary to mTOR inhibition in this study
population.
A second targeted agent, MK-2206, is a novel allosteric Akt
inhibitor that has been tested in adult cancers. In preclinical tri-
als, MK-2206 increased the efficacy of etoposide or rapamycin
in NB cell lines (by MTS assay) (Li et al., 2012). Currently the
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Table 1 | Current pediatric clinical trials targeting the PI3K pathway.
Drug Mechanism Study type Study phase Study aims/findings
Perifosine Akt inhibition Single agent dose escalation
study (NCT00776867)
I Determine molecular predictors of response
(PI3K/AKT/mTOR and RAS/MAPK signaling, cell cycle
markers)
Perifosine+
Temsirolimus
Akt+mTOR
inhibition
Single arm study (NCT01049841) I Establish preliminary data on efficacy of combination
therapy; determine molecular predictors of response
MK-2206 Akt (allosteric)
inhibition
Dose escalation study followed
by treatment at MTD
(NCT01231919)
I/II Evaluate biological activity in tumor and PBMC in
recurrent or refractory leukemia, lymphoma or solid
tumors
Everolimus mTOR
inhibition
Single agent dose escalation
study (Fouladi et al., 2007)
I MTD dose level correlated with degree of mTOR
inhibition in PBMC
Deforolimus mTOR
inhibition
Single agent dose escalation
study (Hartford et al., 2009)
I Toxicity profile similar to other mTOR inhibitors; no
objective disease responses seen
Ridaforolimus mTOR
inhibition
Single agent safety study
(NCT01431534), and in
combination with Dalotuzumab
(NCT01431547)
I Establish MTD, and recommended Phase 2 dose and
potential efficacy of the combination therapy
Temsirolimus mTOR
inhibition
Single agent dose escalation
study (Spunt et al., 2011)
I Well tolerated; MTD not identified
Temsirolimus mTOR
inhibition
Single agent study (Geoerger
et al., 2012)
II Did not meet criteria to continue study as single
agent; significant number with disease stabilization
Temsirolimus mTOR
inhibition
Combination therapy with
Cixutumumab (Naing et al., 2011)
I Well tolerated
Temsirolimus mTOR
inhibition
Combination therapy with
liposomal Doxorubicin (Thornton
et al., 2013)
I MTD defined, toxicity profile acceptable; combination
therapy increased exposure to the active metabolite
of Temsirolimus
Temsirolimus mTOR
inhibition
Combination therapy with
Cixutumumab (NCT01614795)
II Evaluate IGF-1R, insulin receptor, ERK, RON, mTOR
activation in refractory or recurrent sarcomas
Temsirolimus mTOR
inhibition
Combination with Irinotecan,
Temozolomide
(NCT01141244/COG-ADVL0918)
I In younger patients with recurrent or refractory solid
tumors; establish MTD and efficacy of combination
therapy
Rapamycin
(Sirolimus)
mTOR
inhibition
Combination with Topotecan,
Cyclophosphamide
(NCT01670175)
I Determine dose-limiting toxicity, antitumor activity,
biologic and anti-angiogenic effects of drug
combination
Rapamycin
(Sirolimus)
mTOR
inhibition
Single arm efficacy study
(NCT01265030)
I Determine tolerability of preoperative administration
in children and young adults with desmoid-type
fibromatosis; evaluate disease recurrence, pain
improvement, mTOR pathway activation
Rapamycin
(Sirolimus)
mTOR
inhibition
Combination with Vinblastine
(NCT01135563)
I In relapsed solid tumors including selected brain
tumors and lymphoma; establish MTD and response
to combination therapy
Enzastaurin PKC-β
inhibition
Fine et al. (2005) II In recurrent glioblastoma multiforme; good
preliminary radiographic response
Enzastaurin PKC-β
inhibition
Randomized trial comparing
Lomustine (Wick et al., 2010)
III No significant differences on interim analysis; early
study termination
MTD, maximum-tolerated dose; PBMC, peripheral blood mononuclear cells.
Frontiers in Oncology | Pediatric Oncology April 2013 | Volume 3 | Article 93 | 6
Loh et al. PI3K/Akt pathway in pediatric solid tumors
COG is enrolling participants with refractory solid malignan-
cies and recurrent or refractory leukemia (NCT01231919) on a
phase I/II trial with MK-2206 to determine the MTD and tox-
icities of this agent. The study also will evaluate the biological
activity of MK-2206 by measuring PI3K/Akt/mTOR signaling in
tumor and peripheral blood mononuclear cells (PBMCs) and
measure the expression of biomarkers related to Akt activation
phenotypes.
There are several PI3K agents currently in adult phase 1/2 clin-
ical trials. Based on favorable preclinical evidence (Maira et al.,
2008; Serra et al., 2008; Brachmann et al., 2009; Maira, 2011; Ben-
dell et al., 2012; Koul et al., 2012), pediatric preclinical testing
is underway for two of these agents: NVP-BKM-120, a selective
inhibitor of PI3K, and NVP-BEZ-235 a dual mTOR and PI3K
inhibitor (Federico, 2012). Results obtained in pediatric NB cell
lines are promising and testing on xenografts is currently underway
(Federico, 2012).
TARGETING mTOR IN PEDIATRIC SOLID MALIGNANCIES
There is significantly more clinical experience with mTOR
inhibitors in pediatrics. While there is clear efficacy in preclini-
cal cancer models, the clinical application of these agents remains
under investigation.
In 2007, results of a phase I study of everolimus in pediatric
patients with refractory solid tumors were published (Fouladi
et al., 2007). Continuous oral administration was well tolerated
at the MTD of 5 mg/m2, a dose level which correlated with sig-
nificant inhibition of the mTOR pathway signaling in PBMCs. A
second mTOR inhibitor, Deforolimus, was subsequently evaluated
in a phase I trial in pediatric patients with advanced malignan-
cies (Hartford et al., 2009). The drug was again well tolerated
with one partial response and 21 patients with stable disease (12
progressive disease). A similar toxicity and pharmacokinetic pro-
file to other mTOR inhibitors was observed, though no objective
disease responses were observed. The third mTOR inhibitor to
be evaluated in phase I trials, temsirolimus, followed in 2011
(Spunt et al., 2011). The drug was very well tolerated and an MTD
was not identified. After two courses of therapy, 1/13 evaluable
patients achieved CR (NB) and 5/13 had stable disease. Based
on these results, a phase II trial of temsirolimus in children and
adolescents with high-grade glioma (HGG), NB, and RMS was
initiated (Geoerger et al., 2012). At a dose of 75 mg/m2 admin-
istered intravenously once weekly for 12 weeks, no cohort met
criteria for continued enrollment with only one partial response
reported (NB). However, disease stabilization was observed in
7/17 with HGG, 6/19 with NB, and 1/16 with rhabdomyosar-
coma. The most common treatment related adverse effects were
thrombocytopenia, hyperlipidemia, and asthenia. While this drug
did not meet criteria in this study to continue investigation as
a single agent, the promising observation of disease stabilization
in heavily pretreated patients with relapsed or refractory disease
certainly merits further evaluation in combination therapy. The
most recent mTOR inhibitor under evaluation in a phase I clinical
trial is Ridaforolimus, both alone (NCT01431534) and in potential
combination with Dalotuzumab (NCT01431547).
Several clinical studies are further investigating the impact of
mTOR inhibition in combination with other agents in pediatric
solid malignancies. Most recently, findings have been published
from a Phase I/II study of the use of temsirolimus and liposomal
doxorubicin in refractory or recurrent bone or soft tissue sar-
comas. Of 15 patients enrolled in the phase I study, 7 were
under 21 years of age. Toxicities were manageable, and mostly
hematologic. Pharmacokinetics of temsirolimus were not altered
by co-administration with liposomal doxorubicin, but increased
exposure to its active metabolite, sirolimus. Progression-free sur-
vival appeared to be superior to other trials with either agent
given alone. The Phase 2 portion of the study is ongoing, along
with pharmacodynamics studies to test if temsirolimus over-
comes inherent chemoresistance of sarcoma stem cells in vivo
(Thornton et al., 2013). A Phase I study of the combination
of rapamycin (sirolimus), cyclophosphamide, and topotecan, all
given by oral administration, in pediatric and young adult patients
with relapsed and refractory solid tumors opened in August 2012
(NCT01670175). Sirolimus was paired with vinblastine in a phase
I trial for recurrent or refractory solid tumors including central
nervous system tumors that opened in 2010 (NCT01135563);
no results have been published to date. Another Phase II trial
opened in June 2012 to investigate the combination therapy of
temsirolimus with Cixutumumab, an IGF-1R inhibitor, in refrac-
tory or recurrent sarcomas (NCT01614795, COG-ADVL1221)
after promising results were reported in patients within this cohort
during the Phase I trial (Naing et al., 2011). While IGF-1R antag-
onists showed more preclinical promise than clinical efficacy as
single agent therapy, they may be useful in combination therapy
(Wagner and Maki, 2013). The therapy was well tolerated in the
phase I with most common dose-limiting toxicities of mucositis,
febrile neutropenia, and thrombocytopenia. Temsirolimus has also
been paired with irinotecan and temozolomide (NCT01141244,
COG-ADVL0918) in a phase I study for young patients with
relapsed or refractory solid tumors. Finally, a pilot study evalu-
ating sirolimus in children and young adults with desmoid-type
fibromatosis (NCT01265030) opened in December 2010 and is
currently recruiting patients. Rationale for this trial is based on
recent evidence that deregulation of the mTOR cell prolifera-
tion/survival pathway may play an important role in tumor biology
when the APC/B-catenin or WNT/CTNNB1 signaling pathway is
disrupted (Laguë et al., 2008; Pressey et al., 2010) as occurs in
desmoid tumors.
For patients with hematologic malignancies, there is a phase
I trial utilizing temsirolimus in combination with other standard
agents for relapsed ALL and NHL (NCT0164197) and another
phase I trial investigating the addition of everolimus to multia-
gent re-induction chemotherapy for pediatric patients with ALL in
first bone marrow relapse (NCT01523977). A recent review sum-
marized abnormalities in the PI3K/Akt/mTOR signaling pathway
in hematologic malignancies and reviewed the results of preclin-
ical and clinical research supporting the use of these agents for
pediatric patients with these cancers (Barrett et al., 2012). Recent
preclinical investigation indicates that mTOR inhibition may also
disrupt leukemia/stromal interactions, leading to antitumor effect
by a different mechanism (Zeng et al., 2012).
In tuberous sclerosis, the associated inactivating mutations of
TSC1 and TSC2 result in constitutive activation of the mTOR
pathway independent of upstream PI3K/Akt stimulation. For
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patients with tuberous sclerosis who develop subependymal giant-
cell astrocytomas, everolimus therapy has been shown to reduce
tumor volume and seizure frequency (Krueger et al., 2010), and
with further long-term study, may provide an alternative to
surgical resection.
CHALLENGES ASSOCIATED WITH INDIVIDUALIZED PI3K TREATMENT
The development of targeted PI3K therapies will likely lead to the
addition of these antagonists to existing therapy options, alone
or in combination with background treatments (chemotherapy,
surgery, radiotherapy), and eventually offer enhanced treatment
schemes to children with solid tumors. Nevertheless, despite the
promise emerging from these targeted compounds, the ability to
identify patients’ subgroups and response predictive factors will
be crucial in obtaining the greatest benefit with minimal toxic-
ity. The utility of biomarkers related to PI3K signaling pathway
and the appropriate patient selection based on the expression
of relevant therapeutic targets in tumors represents an obsta-
cle regarding the most optimal application of PI3K antitumor
agents. For example, PTEN, pAkt, p27, and pS6 were found to
be informative markers of the mTOR pathway for patient selec-
tion in predicting the response to mTOR inhibitors for renal
cell carcinoma (Pantuck et al., 2007). Other molecular patterns
evaluating the effects of mTOR inhibitors include overexpression
of anti apoptotic proteins (Bcl2) that may serve as a surrogate
marker for rapalog resistance (Delbaldo et al., 2011). Lastly, the
activation of alternative survival pathways such as deregulated
KRAS has been shown to bypass Everolimus-mediated mTOR
inhibition (Delbaldo et al., 2011). Given the potential hurdles
associated with identifying validated predictive biomarkers for
PI3K therapy, it is obvious molecular parameters need to be opti-
mized to better select patients. Other unsolved questions remain,
such as the study of the efficacy of the drugs in a sufficient
number of pediatric patients and the use of pharmacodynamic
models to help to define response predicting factors for these
specific targeted agents. As these treatments will enter routine
practice over the next few years, overcoming the challenges associ-
ated with the rational use of targeted PI3K anticancer therapies
will help evolve the next generation of personalized pediatric
oncology care.
CONCLUSION
In summary, our clinical experience with agents that target the
PI3K pathway is growing. Lessons from adult and pediatric trials
underscore the importance of incorporating agents that target spe-
cific tumorigenic pathways in rationally designed combinatorial
regimens, especially when there is strong mechanistic rationale and
preclinical evidence of synergistic activity. Preclinical comprehen-
sive trials that incorporate pharmacokinetics, tumor biomarkers
to assess molecular targets, and a relevant dosing schedule with
metrics that mirror clinical evaluations for assessment of tumor
response can help identify the targeted agents and combinations
with the best potential for moving from the bench to the bedside
in future clinical trials.
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